Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.


TSXV:VM - Post by User

Post by argeliomon Jan 12, 2022 3:40pm
361 Views
Post# 34309894

VM is in the Pharma business, not mining

VM is in the Pharma business, not miningThe Willis brothers made a strategic decision to move away from basic mining and enter a specific Pharmaceutical niche where they will enjoy a clear cost competitive advantage plus offer  radiocontrast clients a non China option. They will soon start generating cash flow by start selling by mid 2022 a portion of their product line in Canada using third party sourcing. Long term, they will significanly improve margins by developing their own API minerals source (Francis Creek) and GMP plant scheduled to start production by mid 2023.
I like their understated management process.They had promised the Market their PEA early 2022 and they delivered!! I will bet that the Preliminary Feasibility Report will be delivered before the date promised in the presentation.Also, I am really impressed with the industry consultants supporting VM.
https://voyageurpharmaceuticals.ca/wp-content/uploads/2021/09/Voyageur-Investor-Deck-Oct-2021.pdf 
<< Previous
Bullboard Posts
Next >>